IQM
IQM Quantum Computers (IQM), the European leader in quantum computers, announced today it has been selected to deliver quantum processing units for the first Spanish quantum computer to be installed at the Barcelona Supercomputing Center (BSC) and integrated into the MareNostrum 5 supercomputer, the most powerful in Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005345/en/
IQM Quantum Computer opened (Photo: Business Wire)
IQM is a member of the consortium led by Spanish companies Qilimanjaro Quantum Tech and GMV that was selected by Quantum Spain, an initiative promoted by the Ministry of Economic Affairs and Digital Transformation through the Secretary of State for Digitalisation and Artificial Intelligence (SEDIA) in December 2022, to build the first quantum computer for public use in Southern Europe.
Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said, “This is a significant announcement for IQM. We have the right background and experience in developing quantum processors, computers, and national quantum ecosystems. We are looking forward to working with Qilimanjaro Quantum Tech and are delighted to be part of such a strong consortium and play an important role by providing quantum processing units for this notable project.”
The integration of the quantum computer into MareNostrum 5 will have the potential to significantly increase the impact of research and innovation by enabling solutions that complement the capabilities of existing supercomputers, which will be available to the research community, companies, and public organisations, and by strengthening technological and industrial development in Spain and the creation of highly qualified jobs.
“We are delighted to include the expertise of a great player such as IQM to support us developing this innovative system, that will be purely based on Spanish and European technology. We are sure that this will be a very fruitful collaboration and we are looking forward to be partnering with IQM,” said Victor Canivell, Co-founder and CEO of Qilimanjaro.
Jani Heikkinen, Head of Business Development and Country Manager for Spain, said, “This is another example of our European leadership, demonstrating our commitment to advancing the Spanish quantum ecosystem in collaboration with both public and private institutions. Through our office in Madrid, we are also able to provide the necessary support for this project.”
About IQM Quantum Computers
IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 240 employees with offices in Singapore, Paris, Madrid, Munich, and Espoo.
About Qilimanjaro
Qilimanjaro Quantum Tech is a deep-tech startup that brings practical applications of quantum computing to the market in a shorter timeframe than digital quantum computers, by using a different but complementary model of quantum computation: the analog model.
Qilimanjaro creates a coherent quantum annealer accessible via our cloud to run real-world applications such as optimisation tasks in the logistics, finance, and energy sector, among others, and quantum simulation of chemical and physical processes, very present in the materials and pharmaceutical research industries. Qilimanjaro aims at providing its clients with a faster, more accurate and sustainable solution to their computing problems.
It has closed significant customer contracts since its first year of operation and has become a key contributor to the European Commission’s AVaQus H2020 project on coherent quantum annealing. Qilimanjaro is a spin-off from the Barcelona Supercomputer Center (BSC), the University of Barcelona (UB) and the Institute of High-Energy Physics (IFAE).
About GMV
GMV is a privately owned technology business group founded in 1984 and trading on a worldwide scale in the following sectors: Space, Aeronautics, Defense and Security, Cybersecurity, Intelligent Transportation Systems, Automotive, Healthcare, Telecommunications and IT for government authorities and major corporations. In 2021, it had revenues of nearly 260 million euros. Working with a staff of over 3,000, the company now runs subsidiaries in Spain, USA, Germany, France, Poland, Portugal, Romania, UK, The Netherlands, Belgium, Malaysia, and Colombia. Seventy five percent of its turnover comes from international projects on all five continents. The company's growth strategy is based on continuous innovation, and it plows back 5% of its turnover into inhouse R&D. GMV has reached CMMI level 5, the world's most prestigious model in terms of enhancing an organization’s process capability, and it has numerous international patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom